|
See related Pariet enteric-coated tab information |
|
|
|
Manufacturer |
Eisai |
|
Distributor |
Hong Kong: DKSH/Macau: Agencia Lei Va Hong |
|
Contents |
Na rabeprazole |
|
Indications |
Duodenal, gastric & stromal ulcers, reflux oesophagitis, GERD maintenance, symptomatic GERD, Zollinger-Ellison syndrome, H. pylori eradication.
Click to view Pariet detailed prescribing infomation |
|
Dosage |
Adult & elderly Duodenal, gastric & stromal ulcer, reflux oesophagitis & GERD maintenance 10-20 mg once daily. Symptomatic GERD 10 mg once daily. Subsequent symptom control using an on-demand regimen taking 10 mg once daily when needed. Zollinger-Ellison syndrome Individualised dosage. A starting dose of 60 mg daily & doses up to 100 mg daily or 60 mg bd have been used. H. pylori eradication 10 mg w/ clarithromycin 200 mg & amoxicillin 750 mg. 20 mg w/ clarithromycin 500 mg & amoxicillin 1 g. All bd for 1 wk. If the above treatment fails, 10 mg w/ metronidazole 200 mg & amoxicillin 750 mg, all bd for 1 wk is considered.
Click to view Pariet detailed prescribing infomation |
|
Overdosage |
View Pariet overdosage for action to be taken in the event of an overdose. |
|
Administration |
May be taken with or without food (Swallow whole, do not chew/crush.). |
|
Contraindications |
Hypersensitivity to substituted benzimidazoles. Pregnancy & lactation.
Click to view Pariet detailed prescribing infomation |
|
Special Precautions |
Exclude gastric or oesophageal malignancy prior to treatment. Regular surveillance for long-term treatment. May impair ability to drive or operate machine. Severe hepatic dysfunction. Childn.
Click to view Pariet detailed prescribing infomation |
|
Adverse Drug Reactions |
Infection; insomnia; headache, dizziness; cough, pharyngitis, rhinitis; diarrhoea, vomiting, nausea, abdominal pain, constipation, flatulence; nonspecific & back pain; asthenia, flu-like illness.
View ADR Monitoring Form |
|
Drug Interactions |
Decrease ketoconazole serum levels; increases trough digoxin serum levels. Atazanavir/ritonavir.
View more drug interactions with Pariet |
|
Pregnancy Category (US FDA) |
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters). |
|
Caution For Usage |
For caution against possible variation of physical aspect of medicine... click to view Pariet detailed prescribing infomation |
|
Storage |
View Pariet storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Pariet description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Pariet mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
Special Feature |
Researched & developed in Japan by Eisai Co. LtdUS FDA Approved |
